Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 6 | 2021 | 690 | 1.170 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2016 | 14 | 0.560 |
Why?
|
| Pylorus | 1 | 2016 | 28 | 0.550 |
Why?
|
| Gastric Emptying | 1 | 2016 | 94 | 0.540 |
Why?
|
| Bile Ducts, Intrahepatic | 2 | 2007 | 334 | 0.520 |
Why?
|
| Gastroparesis | 1 | 2016 | 72 | 0.510 |
Why?
|
| Jejunum | 1 | 2016 | 216 | 0.500 |
Why?
|
| Drainage | 4 | 2019 | 416 | 0.500 |
Why?
|
| Stomach | 1 | 2016 | 387 | 0.440 |
Why?
|
| Pancreaticojejunostomy | 1 | 2012 | 14 | 0.430 |
Why?
|
| Pancreatic Fistula | 2 | 2014 | 99 | 0.430 |
Why?
|
| Cyanoacrylates | 1 | 2012 | 41 | 0.420 |
Why?
|
| Bile Duct Neoplasms | 2 | 2007 | 493 | 0.420 |
Why?
|
| Cholangiocarcinoma | 2 | 2007 | 493 | 0.420 |
Why?
|
| Tissue Adhesives | 1 | 2012 | 51 | 0.420 |
Why?
|
| Hepatic Stellate Cells | 1 | 2011 | 30 | 0.410 |
Why?
|
| Cell Transplantation | 1 | 2011 | 85 | 0.410 |
Why?
|
| Hepatectomy | 2 | 2008 | 1011 | 0.390 |
Why?
|
| Liver | 3 | 2011 | 2961 | 0.390 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2010 | 2027 | 0.380 |
Why?
|
| Postoperative Complications | 6 | 2019 | 5542 | 0.370 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 142 | 0.370 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2010 | 145 | 0.360 |
Why?
|
| Ampulla of Vater | 1 | 2010 | 155 | 0.350 |
Why?
|
| Yttrium Radioisotopes | 5 | 2009 | 178 | 0.350 |
Why?
|
| Hepatocytes | 1 | 2011 | 351 | 0.350 |
Why?
|
| Tissue Engineering | 1 | 2011 | 269 | 0.340 |
Why?
|
| Liver Neoplasms | 7 | 2010 | 4557 | 0.330 |
Why?
|
| Jehovah's Witnesses | 1 | 2007 | 21 | 0.310 |
Why?
|
| Pilot Projects | 4 | 2016 | 2803 | 0.270 |
Why?
|
| Perfusion | 1 | 2007 | 293 | 0.270 |
Why?
|
| Obesity, Morbid | 1 | 2008 | 224 | 0.270 |
Why?
|
| Liver Transplantation | 3 | 2011 | 1112 | 0.260 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2007 | 275 | 0.260 |
Why?
|
| Pancreatectomy | 3 | 2019 | 652 | 0.260 |
Why?
|
| Tumor Burden | 1 | 2010 | 1987 | 0.240 |
Why?
|
| Postoperative Care | 2 | 2019 | 739 | 0.220 |
Why?
|
| Patient Selection | 1 | 2010 | 2055 | 0.210 |
Why?
|
| B7 Antigens | 1 | 2020 | 84 | 0.180 |
Why?
|
| Carcinosarcoma | 1 | 2021 | 146 | 0.170 |
Why?
|
| Microspheres | 3 | 2009 | 210 | 0.160 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 117 | 0.150 |
Why?
|
| Nutritional Support | 1 | 2017 | 80 | 0.140 |
Why?
|
| Pyloric Antrum | 1 | 2016 | 60 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2019 | 12873 | 0.140 |
Why?
|
| Middle Aged | 15 | 2021 | 86204 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 130 | 0.130 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 1081 | 0.120 |
Why?
|
| Angiography | 2 | 2005 | 360 | 0.120 |
Why?
|
| Glucose | 2 | 2011 | 1248 | 0.110 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 10331 | 0.110 |
Why?
|
| Treatment Outcome | 9 | 2019 | 32848 | 0.110 |
Why?
|
| Female | 17 | 2021 | 141928 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1085 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2009 | 1301 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2012 | 257 | 0.100 |
Why?
|
| Lactates | 1 | 2011 | 112 | 0.100 |
Why?
|
| Humans | 23 | 2023 | 261506 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 1054 | 0.100 |
Why?
|
| Jejunostomy | 2 | 2009 | 52 | 0.100 |
Why?
|
| Quality of Life | 2 | 2023 | 4532 | 0.100 |
Why?
|
| Aged | 10 | 2020 | 70117 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5061 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1362 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2011 | 626 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2010 | 67 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1082 | 0.090 |
Why?
|
| Male | 12 | 2020 | 123000 | 0.080 |
Why?
|
| Length of Stay | 2 | 2014 | 1900 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 665 | 0.080 |
Why?
|
| Hemodilution | 1 | 2007 | 18 | 0.080 |
Why?
|
| Patient Readmission | 1 | 2012 | 548 | 0.080 |
Why?
|
| Procaine | 1 | 2007 | 8 | 0.080 |
Why?
|
| Reoperation | 1 | 2012 | 1382 | 0.080 |
Why?
|
| Potassium Chloride | 1 | 2007 | 55 | 0.080 |
Why?
|
| Mannitol | 1 | 2007 | 54 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 1489 | 0.080 |
Why?
|
| Hepatic Artery | 2 | 2005 | 240 | 0.080 |
Why?
|
| Swine | 1 | 2011 | 1541 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 1724 | 0.070 |
Why?
|
| Oxygen | 1 | 2011 | 754 | 0.070 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2007 | 42 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2010 | 233 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2020 | 9244 | 0.070 |
Why?
|
| Risk Factors | 3 | 2019 | 17523 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 133 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2010 | 13658 | 0.070 |
Why?
|
| Radiography, Interventional | 2 | 2005 | 305 | 0.070 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 190 | 0.070 |
Why?
|
| Gastritis | 1 | 2009 | 373 | 0.070 |
Why?
|
| Hypothermia, Induced | 1 | 2007 | 170 | 0.070 |
Why?
|
| Blood Loss, Surgical | 1 | 2007 | 309 | 0.070 |
Why?
|
| Adult | 6 | 2020 | 77950 | 0.060 |
Why?
|
| Cell Survival | 1 | 2011 | 3045 | 0.060 |
Why?
|
| Logistic Models | 1 | 2012 | 3441 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 4298 | 0.060 |
Why?
|
| Melphalan | 1 | 2007 | 834 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 29902 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 14889 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 1021 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2011 | 5637 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2009 | 1411 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 4988 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 2170 | 0.050 |
Why?
|
| Enterocytes | 1 | 2021 | 68 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2018 | 37905 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 551 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6207 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2007 | 3005 | 0.050 |
Why?
|
| Cisplatin | 1 | 2007 | 2432 | 0.040 |
Why?
|
| Prognosis | 2 | 2023 | 21713 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2594 | 0.040 |
Why?
|
| Amylases | 1 | 2019 | 66 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2011 | 7226 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 403 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 2 | 2009 | 62 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 38 | 0.040 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 5673 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2009 | 7551 | 0.030 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 7789 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 337 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 8865 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 337 | 0.030 |
Why?
|
| Neoplasms | 1 | 2020 | 15193 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 85 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 1506 | 0.030 |
Why?
|
| Malnutrition | 1 | 2017 | 218 | 0.030 |
Why?
|
| Pancreas | 1 | 2017 | 718 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 2231 | 0.030 |
Why?
|
| Young Adult | 1 | 2010 | 21445 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 10035 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 10001 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 5687 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3890 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2021 | 4078 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 2218 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 7548 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2009 | 134 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2009 | 81 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 2278 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 171 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 4367 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2005 | 3842 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 3341 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2009 | 7702 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2009 | 316 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2008 | 310 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 59536 | 0.020 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2005 | 76 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 5047 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2008 | 9180 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 12926 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2009 | 524 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2005 | 181 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4320 | 0.010 |
Why?
|
| United States | 1 | 2020 | 15433 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 6682 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 15862 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 14289 | 0.010 |
Why?
|